Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.
Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
